• On 19 March 2026, LivaNova announced that the FDA granted premarket approval for its aura6000 System, a proximal hypoglossal nerve stimulation therapy for adult patients with moderate to severe obstructive sleep apnea who cannot use or benefit from first-line treatments like positive airway pressure.
• Backed by the rigorously designed OSPREY randomized controlled trial and plans for an MRI‑compatible, rechargeable next‑generation device, this approval opens a new neuromodulation avenue for LivaNova in the large obstructive sleep apnea treatment market.
• Next, we’ll examine how this FDA approval and its OSPREY-backed efficacy data could reshape LivaNova’s broader neuromodulation-focused investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

LivaNova Investment Narrative Recap

To own LivaNova, you have to believe in its ability to turn a differentiated neuromodulation portfolio into sustainable profits, while managing reimbursement, competition, and R&D driven margin pressure. The aura6000 approval strengthens the neuromodulation story and could become a key medium term growth driver, but near term, the most important catalyst remains execution against 2026 revenue guidance and the biggest risk is that elevated R&D and launch spending keep profitability under pressure. The impact on that risk looks meaningful but still unproven.

Among recent updates, the 2026 guidance for 6 to 7 percent constant currency revenue growth matters most alongside aura6000. It sets the financial bar against which the OSA launch, Essenz perfusion roll out, and broader neuromodulation investments will be judged. If commercialization of aura6000 ramps slower or proves more expensive than expected, it could make delivering that growth with acceptable margins harder, even if top line momentum holds up.

Yet investors should also weigh the risk that higher OSA and neuromodulation investment, which the most bearish analysts already saw pushing toward US$186.5 million of earnings only by 2028, could...

LivaNova’s narrative projects $1.7 billion revenue and $173.6 million earnings by 2029. This requires 7.1% yearly revenue growth and a $416.1 million earnings increase from -$242.5 million today.

Uncover how LivaNova's forecasts yield a $79.91 fair value, a 29% upside to its current price.

Exploring Other Perspectives

While aura6000 looks like a new growth leg, the most pessimistic analysts were already cautious, assuming only about 5.9 percent annual revenue growth and earnings of roughly US$186.5 million by 2028, so you should recognise how far views can differ before this approval and consider how those expectations might shift now.

Explore 2 other fair value estimates on LivaNova - why the stock might be worth as much as 58% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your LivaNova research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

No Opportunity In LivaNova?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.